TL;DR
- SLU-PP-332 is an ERRα/β/γ agonist — a small molecule that activates estrogen-related receptors without touching estrogen receptors themselves.
- Mechanism: ERR activation forces skeletal muscle into an oxidative, fatigue-resistant, type I fiber phenotype — essentially tricking muscle into thinking you ran a marathon.
- Who it’s for: Endurance athletes, metabolically broken individuals, and anyone who wants the benefits of cardio without the time investment.
- Key differentiator: EC50 of 98 nM at ERRα — one of the most potent exercise mimetics ever synthesized. Works where GW501516 (Cardarine) left off, without the PPARδ carcinogenicity concerns.
- Natural Plus angle: Stack SLU-PP-332 on top of real training and you don’t just mimic exercise — you multiply it. The governors come off.
What Is SLU-PP-332?
SLU-PP-332 is a synthetic small molecule developed at Saint Louis University by the Burris lab that acts as a pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ). Unlike steroidal compounds or PPAR agonists, ERR targeting is a fundamentally different lever — one that most of the supplement world still hasn’t caught onto.
I’ve been tracking this compound since the original Molecular Metabolism paper dropped. When I tell you it’s the closest thing to a needle that shifts resting phenotype toward endurance-trained, I’m not overhyping. The published EC50 is 98 nM at ERRα — for reference, that’s pharmaceutical-grade potency.
Deep Biochemistry: How ERR Activation Rewires Metabolism
The estrogen-related receptors are orphan nuclear receptors — they share structural homology with classical estrogen receptors but bind no known endogenous ligand. Their job is metabolic. ERRα in particular is the master transcriptional regulator of mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation genes.
When SLU-PP-332 binds ERRα, it triggers coactivator recruitment (primarily PGC-1α) and drives transcription of a whole cassette of oxidative genes: citrate synthase, medium-chain acyl-CoA dehydrogenase, cytochrome c, and dozens of nuclear-encoded mitochondrial proteins. The downstream consequence is that skeletal muscle literally grows new mitochondria and converts fast-twitch glycolytic fibers toward slow-twitch oxidative fibers.
In the original mouse study (Molecular Metabolism, 2024), sedentary mice treated with SLU-PP-332 showed 70% increased running time to exhaustion and dramatic improvements in oxygen consumption — changes that normally require weeks of endurance training. Importantly, this happens without weight loss from reduced food intake. The mice eat normally but burn more.
Per the Tony Huge Laws of Biochemistry Physics, Law 1 (Governors vs Accelerators) is the key frame here. Most people think of exercise as pushing harder on the accelerator: more reps, more minutes, more intensity. But what exercise actually does is release a governor — it downregulates the inhibitors of mitochondrial biogenesis by activating PGC-1α. SLU-PP-332 hijacks this pathway directly. It doesn’t push the gas pedal harder; it reaches under the hood and cuts the cable on the transcriptional brake that keeps your muscle in glycolytic, low-output mode.
Tony Huge Natural Plus Protocol
My current protocol guidance for SLU-PP-332 (based on extrapolation from rodent dosing, caveat emptor — no human trials yet):
- Dose: 5-10 mg daily, subcutaneous injection or oral (bioavailability still being worked out).
- Timing: Pre-workout on training days. The research protocol dosed 30-60 min before exercise to stack with endogenous PGC-1α activation.
- Cycle: 6-8 weeks on, 4 weeks off. We don’t yet know the long-term safety profile, so conservative cycling is warranted.
- Cycle support: Defend is recommended to protect the liver since the compound undergoes hepatic metabolism.
- Bloodwork to monitor: Liver enzymes (ALT, AST), lipid panel, fasting glucose. ERR activation shifts lipid metabolism — you’ll likely see triglycerides drop.
This is NOT a lose-weight-on-the-couch compound the way certain influencers will try to sell it. It’s an amplifier of training. Use it during blocks of hard conditioning work and you’ll see the most dramatic results.
Stacking Recommendations
| Stack Compound | Pathway | Why It Synergizes |
|---|---|---|
| MOTS-c | Mitochondrial | MOTS-c signals from mitochondria to nucleus; SLU-PP-332 drives the nuclear response. Stack amplifies both directions of mito-nuclear communication. |
| BPC-157 | Repair/angiogenesis | Increased training volume from enhanced endurance creates more tissue stress — BPC-157 keeps tendons and joints from breaking down. |
| CJC-1295 / Ipamorelin | GH/IGF-1 | GH axis is independent of ERR — stacking hits two different receptors for additive metabolic effect (Law 5 of Tony Huge Laws of Biochemistry Physics). |
Target Audience
SLU-PP-332 is ideal for: endurance athletes who’ve plateaued, combat sports competitors cutting weight while maintaining work capacity, metabolically broken individuals with mitochondrial dysfunction (think long COVID, chronic fatigue), and bodybuilders coming off cycles who want to rebuild insulin sensitivity fast. It’s NOT for people who aren’t training — you’ll waste it.
Timeline / Results Table
| Timeframe | What to Expect |
|---|---|
| Week 1-2 | Subtle improvements in cardiac output during steady-state work. Heart rate comes down faster between intervals. |
| Week 4 | Noticeable increase in time to fatigue. Hill repeats that used to crush you become manageable. |
| Week 8 | Body composition shift toward leaner, more vascular appearance. Resting metabolic rate measurably higher. |
| Week 12 | VO2 max improvement comparable to a 12-week endurance block. Mitochondrial density up. |
Interesting Perspectives
Here’s where it gets really interesting. The Burris lab’s 2024 paper wasn’t primarily about athletic performance — it was about treating metabolic disease. The team fed mice a high-fat diet and SLU-PP-332 prevented diet-induced obesity without reducing food intake. The implication is that ERR activation could be a new axis entirely for treating type 2 diabetes and NAFLD, independent of GLP-1 pathways.
A cross-domain connection most people miss: ERRα expression declines with age and is reduced in sarcopenia. This means SLU-PP-332 isn’t just an athletic enhancer — it’s potentially a longevity compound. The pathway overlaps heavily with what caloric restriction does to mitochondria. Several research groups are quietly exploring ERR agonists for age-related muscle wasting.
The contrarian take from my network: SLU-PP-332 may actually be MORE effective in sedentary individuals than in highly trained athletes, because trained athletes already have near-maximal PGC-1α signaling. The governor is already off. The compound shines brightest in people whose baseline is broken.
Emerging research angle: recent work has shown ERRγ (one of the isoforms SLU-PP-332 hits) is expressed in brown adipose tissue. Activating it there may increase thermogenic fat burning — potentially explaining part of the observed weight management effect in high-fat-fed mice.
References
- Billon C, Sitaula S, Banerjee S, et al. “Synthetic ERRα/β/γ agonist induces an ERRα-dependent acute aerobic exercise response and enhances exercise capacity.” Molecular Metabolism, 2024. DOI: 10.1016/j.molmet.2023.101860
- Billon C, et al. “SLU-PP-332, an ERR agonist, enhances exercise capacity and cardiac function.” PubMed, 2023. PMID: 37739806
- Narkar VA, Fan W, Downes M, et al. “Exercise and PGC-1α-independent synchronization of type I muscle metabolism and vasculature by ERRγ.” Cell Metabolism, 2011. DOI: 10.1016/j.cmet.2011.06.019
- Fan W, He N, Lin CS, et al. “ERRγ Promotes Angiogenesis, Mitochondrial Biogenesis, and Oxidative Remodeling in PGC1α/β-Deficient Muscle.” Cell Reports, 2018. DOI: 10.1016/j.celrep.2018.05.085
- Huss JM, Garbacz WG, Xie W. “Constitutive activities of estrogen-related receptors.” Biochimica et Biophysica Acta, 2015. DOI: 10.1016/j.bbadis.2015.06.002
- Burris TP, et al. “Nuclear receptors and metabolism: from feast to famine.” Diabetologia, 2013. DOI: 10.1007/s00125-012-2755-2
Frequently Asked Questions
What is SLU-PP-332?
SLU-PP-332 is a synthetic pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ) developed at Saint Louis University. It acts as an exercise mimetic by directly activating the transcriptional program that endurance training normally triggers — increased mitochondrial biogenesis and oxidative metabolism in skeletal muscle.
What dose of SLU-PP-332 should I use?
Based on rodent studies and extrapolation, 5-10 mg daily is a reasonable starting range. The research protocol dosed before exercise. No human trials have defined optimal dosing yet, so start low and titrate. Cycle 6-8 weeks on, 4 weeks off.
Are there side effects with SLU-PP-332?
Long-term safety in humans is not established. In rodent studies no major toxicity was observed at effective doses. Monitor liver enzymes and lipids. Because it upregulates mitochondrial activity, some users report feeling warmer and having elevated resting heart rate during the first two weeks.
Can I stack SLU-PP-332 with other compounds?
Yes — it stacks exceptionally well with MOTS-c, BPC-157, and GH secretagogues like CJC-1295/Ipamorelin. These all hit independent pathways, so you get additive rather than redundant effects. Avoid stacking with other PPAR or ERR-targeting compounds simultaneously.
Who should use SLU-PP-332?
It’s best suited for endurance athletes, combat sports competitors, metabolically compromised individuals (diabetes, NAFLD, long COVID), and aging populations looking to preserve mitochondrial function. If you don’t train, you’re wasting it — it amplifies training adaptations rather than replacing them.
For further reading, see my breakdowns of advanced peptide protocols, the CagriSema dual-hormone fat loss stack, and the longevity compound library for deeper cuts on what actually works.